Maxim Ceplene fails melanoma study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Maxim is deciding whether to pursue a malignant melanoma indication for Ceplene (histamine dihydrochloride) after the H2 receptor agonist failed a confirmatory Phase III trial for the indication, the company says Sept. 20. The 230-patient trial was conducted under a special protocol assessment and evaluated Ceplene in combination with interleukin-2 against IL-2 alone. Ceplene was not significant for the primary endpoint of duration of survival. Maxim will continue pursuit of an acute myeloid leukemia indication for Ceplene based on positive results from a three-year Phase III trial of Ceplene in combination with IL-2. "We will also conduct a review of our pipeline, our operations and resources," the firm said...
You may also be interested in...
Maxim withdraws Ceplene NDA
Maxim is withdrawing the NDA for use of its H2 receptor antagonist Ceplene (histamine dihydrochloride) in malignant melanoma patients with liver metastases, the firm announces Nov. 1. "Our focus has shifted to potential filings for…acute myeloid leukemia based on our positive Phase III trial reported this summer, as well as partnering efforts for both Ceplene and our apoptosis compounds," Maxim says. Negative results for a confirmatory Phase III trial in advanced malignant melanoma were reported in September; the company said it would evaluate whether to pursue the indication (1Pharmaceutical Approvals Monthly Oct. 1, 2004, In Brief)...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.